Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria

Parkinson’s disease (PD) is a major cause of age-related morbidity and mortality, present in nearly 1% of individuals at ages 70–79 and ∼2.5% of individuals at age 85. L-DOPA (L-dihydroxyphenylalanine), which is metabolized to dopamine by dopa decarboxylase, is the primary therapy for PD, but may al...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Free radical biology & medicine 2001-04, Vol.30 (8), p.924-931
Hauptverfasser:	Kristal, Bruce S, Conway, Ann D, Brown, Abraham M, Jain, Jinesh C, Ulluci, Paul A, Li, Shu Wen, Burke, William J
Format:	Artikel
Sprache:	eng
Schlagworte:	3,4-Dihydroxyphenylacetaldehyde 3,4-Dihydroxyphenylacetic Acid - analogs & derivatives 3,4-Dihydroxyphenylacetic Acid - antagonists & inhibitors 3,4-Dihydroxyphenylacetic Acid - metabolism 3,4-Dihydroxyphenylacetic Acid - toxicity 4-Aminobenzoic Acid - pharmacology Aminobenzoates Animals Aristolochic Acids Cell Death - drug effects Cell Differentiation - drug effects Cyclosporine - pharmacology Dopamine Dopamine - metabolism Dopamine - pharmacology Dopamine Antagonists - pharmacology Enzyme Inhibitors - pharmacology Free radicals Ion Channels levodopa Male Membrane Proteins - metabolism Mitochondria Mitochondria - drug effects Mitochondria - metabolism Mitochondrial Membrane Transport Proteins Nerve Growth Factor - pharmacology para-Aminobenzoates Parkinson Disease - metabolism Parkinson’s disease PC12 Cells Permeability transition Phenanthrenes - pharmacology Rats Rats, Inbred F344 Reactive species Respiration - drug effects Rotenone - pharmacology Trifluoperazine - pharmacology Uncoupling Agents - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!